The current NSCLC treatment landscape has evolved to include the use of anti–programmed cell death-1 (PD-1) monoclonal antibodies in patients without actionable genetic alterations [6, 7]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.